Sherman Rachel E. 4
4 · Sema4 Holdings Corp. · Filed Jul 26, 2021
Insider Transaction Report
Form 4
Sherman Rachel E.
Director
Transactions
- Award
Stock Option (Right to Buy)
2021-07-22+363,223→ 363,223 totalExercise: $0.77Exp: 2030-02-17→ Class A Common Stock (363,223 underlying)
Footnotes (2)
- [F1]6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- [F2]Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.